Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9512167
APP PUB NO 20140050791A1
SERIAL NO

13989012

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a pure polymorph of Nor-UDCA or Bis-nor-UDCA, or of a pharmaceutically acceptable salt thereof. The invention further provides a pharmaceutical composition comprising the polymorph of the invention, and a method for preparing the polymorph. The invention includes the pharmaceutical use of the polymorph or of the pharmaceutical composition of the invention.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
DR FALK PHARMA GMBH79108 FREIBURG

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Fischer, Erik Vaerlose, DK 20 162
Proels, Markus Freiburg, DE 8 20
Waenerlund, Poulsen Heidi Bagsvaerd, DK 13 56
Wilhelm, Rudolf Bischweier, DE 19 98

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 6, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00